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ABSTRACT
Metabolic networks are highly connected and complex, but a single enzyme, 
O-GlcNAc transferase (OGT) can sense the availability of metabolites and also modify 
target proteins. We show that inhibition of OGT activity inhibits the proliferation of 
prostate cancer cells, leads to sustained loss of c-MYC and suppresses the expression of 
CDK1, elevated expression of which predicts prostate cancer recurrence (p=0.00179). 
Metabolic profiling revealed decreased glucose consumption and lactate production 
after OGT inhibition. This decreased glycolytic activity specifically sensitized prostate 
cancer cells, but not cells representing normal prostate epithelium, to inhibitors of 
oxidative phosphorylation (rotenone and metformin). Intra-cellular alanine was 
depleted upon OGT inhibitor treatment. OGT inhibitor increased the expression 
and activity of alanine aminotransferase (GPT2), an enzyme that can be targeted 
with a clinically approved drug, cycloserine. Simultaneous inhibition of OGT and 
GPT2 inhibited cell viability and growth rate, and additionally activated a cell death 
response. These combinatorial effects were predominantly seen in prostate cancer 
cells, but not in a cell-line derived from normal prostate epithelium. Combinatorial 
treatments were confirmed with two inhibitors against both OGT and GPT2. Taken 
together, here we report the reprogramming of energy metabolism upon inhibition 
of OGT activity, and identify synergistically lethal combinations that are prostate 
cancer cell specific.
INTRODUCTION
Prostate cancer is the most common male cancer 
in Europe and the USA. The androgen receptor (AR), a 
member of the nuclear hormone receptor family, is the 
major target in the treatment of the disease and its function 
is therefore the major focus for research. Enhanced AR 
activity promotes cell survival and proliferation by re-
programming tumour cell metabolism [1-3]. In addition, 
AR re-wires the metabolism of the normal prostate tissue, 
compared to the other differentiated cell and tissue types 
in the human body. The prostate gland secretes high levels 
of citrate, which is brought about by AR-regulated zinc 
accumulation to inhibit cis-aconitase [1]. This leads to 
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decreased TCA cycle activity and ability to produce ATP. 
In the normal prostate tissue, AR additionally promotes 
the expression of lipogenic enzymes [4]. By doing this, 
AR alters the key energy producing and consuming 
mechanisms of the cell, and many of these changes are 
typically associated with proliferating cells.
In prostate cancer, the major traits of the metabolic 
phenotype are similar to what is seen in other cancers: 
increased glycolysis, abnormal phospholipid metabolism 
and dependence on reductive glucose metabolism [5]. It is 
highly likely that some of the metabolic features initially 
found in the normal prostate, are preserved in prostate 
cancer, and can be successfully targeted by repurposing 
metabolic inhibitors developed to treat other diseases. 
Indications that this is feasible have arisen from large 
epidemiological studies which, for example, have revealed 
that the use of the anti-diabetic drug metformin has strong 
effects on prostate cancer risk [6]. In addition, several 
novel compounds targeting cancer-specific metabolic 
abnormalities, such as glutaminase and monocarboxylate 
transporter 1 inhibitors, are currently assessed in clinical 
trials [7].
Metabolic pathways are highly inter-connected 
which complicates drug approaches, as normal cells can 
also be targeted. This challenge has led to the search for 
combinatorial treatment options to specifically target 
the vulnerabilities of cancer cells, which are not able to 
activate appropriate survival pathways upon dual targeting 
and do not cause toxicities in normal cells [8].
One of the key pathways sensing metabolic status 
in cells is the hexosamine biosynthetic pathway (HBP) 
[9]. HBP requires glucose, glutamine, acetate and UTP, 
and is thereby positioned to integrate information on 
the availability of nutrients. HBP produces the high-
energy compound UDP-N-acetyl-D-glucosamine (UDP-
GlcNAc), which is a sugar donor involved in synthesis 
of other nucleotide sugars, complex glycosylation and 
also utilized by O-GlcNAc transferase (OGT) to modify 
target proteins via single sugar conjugation [10, 11]. OGT 
targets key regulators of cell fate, including metabolic 
enzymes such as phosphofructokinase 1 [12], epigenetic 
regulators Oct4 and Sox2 [13] and transcriptional activity 
through glycosylation of the RNA Polymerase II tail 
to affect initiation complex formation [14]. Increased 
OGT expression has been detected in numerous cancers, 
including bladder cancer [15] and lung and colon cancers 
[16]. We recently reported that HBP enzymes are over-
expressed in human prostate cancer patients and that 
three of the four HBP enzymes are induced by androgen 
stimulation [2, 17]. All this has triggered great interest in 
developing small molecule inhibitors to target OGT [18, 
19].
Given the established metabolic re-programming 
of prostate cancer cells, we hypothesised that inhibition 
of OGT activity might be able to distort cancer cell 
metabolism. In this study, we treated prostate cancer cells 
with a commercially available OGT inhibitor ST045849 
and analysed samples with 1H Nuclear Magnetic 
Resonance (NMR) spectroscopy. Treatment with the OGT 
inhibitor led to complete depletion of intracellular alanine. 
Gene expression analysis suggested that alanine was 
consumed by glutamic pyruvate transaminase 2 (alanine 
aminotransferase, GPT2). Combining OGT inhibition with 
GPT2 inhibition induced cell death specifically in prostate 
cancer cells.
RESULTS
Establishment of OGT inhibitor dose that inhibits 
proliferation of cancer cells
OGT activity is important for the proliferation of 
cancer cells, and inhibition of its activity inhibits tumour 
formation and metastasis [17, 20, 21]. These effects 
are mediated in part via down-regulation of oncogenic 
transcription factors such as c-MYC (Figure 1A). Previous 
studies have relied on transcriptomic profiling focusing on 
regulators of cell cycle genes. Given the prominent role 
of OGT as a metabolic integration point, we speculated 
that inhibition of its activity might additionally alter the 
metabolic profile of the cell.
First we wanted to identify an inhibitor dose that 
would modestly inhibit the proliferation of prostate cancer 
cells but ideally have no or low effects in cells representing 
normal prostate tissue. Therefore, we measured the 
viability of LNCaP (a prostate cancer cell line) and of 
PNT2 (a cell line representing normal prostate tissue) cells 
after 96 hours of treatment. This time-point was selected 
since prostate cancer cell proliferation rate is quite low 
and the effects on the metabolome should become clearer 
at late time-points. As expected, and based on previous 
studies [17], OGT inhibitor ST045849 significantly 
inhibited the viability of prostate cancer cells (Figure 1B). 
The same compound also decreased the viability of PNT2 
cells, but to lower extent. We next evaluated the growth 
rate of both cell lines upon treatment with ST045849, 
and found that the higher dose (40µM) led to complete 
inhibition of proliferation in both prostate cancer cells and 
in cells representing normal prostate tissue (Figure 1C). 
Based on these data, we chose to treat cells with 20μM 
ST045849 to study the metabolic response of cells to OGT 
inhibition.
We next assessed if this dose was sufficient to 
decrease total O-GlcNAcylation in cancer cells, but 
observed that cells were able to compensate in the level 
of total protein O-GlcNAcylation at late time-points (data 
not shown), but at 1 hour after treatment with a low dose 
of ST045849 (20µM), we observed prominent decrease 
in the total protein O-GlcNAcylation (Suppl. Figure 1A). 
The observed compensation is not surprising, as it is well 
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Figure 1: Effects of OGT inhibition on cell viability and establishment of the dose for metabolomics. A. Enzymes 
regulating O-GlcNAc cycling. GFPT1 (glutamine--fructose-6-phosphate transaminase 1) is the rate-limiting enzyme in the hexosamine 
(HBP) biosynthetic pathway and directs glucose to the HBP rather than glycolysis. UDP-GlcNAc (UDP-N-acetylglucosamine) is the 
end-product of HBP and is utilized by OGT to modify target proteins via single sugar conjugation. c-MYC is highlighted here as one of 
its targets. ST045849 is a small molecule inhibitor targeting OGT. OGA (N-Acetyl-Beta-D-Glucosaminidase) removes O-GlcNAc from 
target proteins. B. LNCaP and PNT2 cells were treated with the indicated doses of OGT inhibitor ST045849 for 96 hours, and the viability 
was determined with the CellTiter-Glow® (CTG) assay. The data shown is an average of four biological replicates and Standard Error of 
the Mean (SEM) is shown. The significance was assessed with Student’s t-test, ** < 0.01 and *** < 0.001. C. Growth rate of cells after 
indicated treatments. The data shown is an average of four biological replicates with SEM. The significance was assessed with Student’s 
t-test as above, * < 0.05, ** < 0.01 and *** < 0.001, red stars indicate comparison between normal and 20µM ST045849 and blue stars 
indicate comparison between normal and 40µM ST045849. D. Total mRNA was collected from LNCaP cells treated with 20µM OGT 
inhibitor ST045849 for 12, 24, 48 and 96 hours, and analysed with RT-qPCR. OGT inhibitor treated samples were normalized to sample 
without treatment at 12 hours. The data shown is an average of at least three biological replicates with SEM. The significance was assessed 
with Student’s t-test (* < 0.05, ** < 0.01 and *** < 0.001) by comparing untreated sample from the corresponding time point, and each 
colour corresponds to the transcript measurement highlighted with the same colour. E. Protein lysates were harvested at 12, 24, 48 and 96 
hour time-points and blotted for the markers of interest. The data shown is representative of three biological replicates. Densitometry was 
used to quantitate the intensity of each band, AR, c-MYC and CDK1 intensities were normalized to loading control and un-treated sample 
from each time-point was set to 1. F. Potential correlation of CDK1 expression with biochemical recurrence in prostate cancer patients was 
assessed using cBioPortal for Cancer Genomics (http://www.cbioportal.org/) using Taylor & al. data set[25]. Increased expression of CDK1 
predicts biochemical recurrence with p value of 0.00179.
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established that O-GlcNAcylation is tightly regulated 
[17, 22]. This compensation was mediated, at least in 
part, through increased expression of the rate-limiting 
enzyme in the hexosamine biosynthetic pathway, GFPT1 
(Figure 1D and Suppl. Figure 1C, 1D). Interestingly, the 
expression of both OGT and O-GlcNAcase (OGA) were 
increased in the mRNA but not noticeably in protein 
level upon OGT inhibitor treatment. We next assessed 
whether some of the effects previously reported upon 
treatment with ST045849 were seen at a dose of 20μM, 
and observed that the compound led to sustained decrease 
of c-MYC at the 24, 48 and 96 hour time-points (Figure 
1E) [17]. In addition, we assessed the expression levels 
of CDK1, the gene found to be most down-regulated by 
ST045849 treatment [17]. The expression of CDK1 was 
suppressed at 12 hours and this decreased expression 
was maintained until 96 hours, and the same was true in 
protein level (Figure 1D, 1E).
A novel OGT inhibitor, OSMI-1, was recently 
reported with higher specificity against OGT than other 
extant compounds [18, 19]. In an in vitro assay utilizing 
purified OGT, OSMI-1 has a 20-fold lower IC50-value 
once compared to ST045849. OSMI-1 has fewer side 
effects, and compound appears not to affect plasma-
membrane glycosylation, but still requires reasonably high 
doses to induce effects on the total-O-GlcNAc (50µM for 
maximal inhibition) [19]. We first confirmed that OSMI-1 
decreased total-O-GlcNAc (Suppl. Figure 1E). Treatment 
with OSMI-1 led maximally to 60% decrease in CDK1 
mRNA (Suppl. Figure 1F). Importantly, and in agreement 
with ST045849-data, OSMI-1 decreased both c-MYC 
and CDK1 proteins by 40% at 24 and 48hours after the 
treatment (Suppl. Figure 1G). CDK1 phosphorylates 
AR and thereby stabilizes the protein and protein’s 
transcriptional output [23]. As expected based on the 
reported CDK1 function, OGT inhibition also decreased 
AR protein expression (Figure 1E and Suppl. Figure 1G).
So far, we have established an inhibitor dose 
that displayed a clear decrease in the expression of an 
important cell cycle regulator, CDK1 [24], and a decrease 
in the expression of AR, a major drug target in prostate 
cancer. Analysis of a published prostate cancer microarray 
data set [25] revealed that increased expression of CDK1 
predicts prostate cancer recurrence after surgery with high 
significance (p = 0.00179, Figure 1F). Based on these data, 
we decided to analyse the possible metabolic adaptations 
that enable prostate cancer cell survival despite the 
significant down-regulation of prominent prostate cancer 
oncogenes, c-MYC and AR.
Inhibition of O-GlcNAc transferase activity 
inhibits glycolysis
Having established a dose of OGT inhibitor 
ST045849 for metabolic profiling, we used 1H NMR 
spectroscopy to analyse cell culture media of LNCaP 
prostate cancer cells treated with the OGT inhibitor. 
In accordance with growth inhibition, we observed a 
decrease in glucose consumption and in lactate production, 
potentially reflecting the inhibitory effects on cell growth 
(Figure 2A). However, we speculated that the treatment 
imposed a selection pressure on prostate cancer cells 
for a switch in metabolic dependency. Since oxidative 
phosphorylation can be sustained by other substrates 
than glucose we hypothesised that the decreased ability 
of these cells to cope with lower glucose uptake should 
make them sensitive to inhibitors of mitochondrial 
respiration. In order to test this hypothesis, we used two 
compounds: (1) a highly potent mitochondria complex 
1 inhibitor (rotenone) at a dose of 10nM which leads to 
80% decrease in complex 1 activity [26] but has only 
modest effect on viability, and (2) metformin (used at a 
1mM concentration), another complex 1 inhibitor with less 
specificity but used in clinical setting [27]. Treatment of 
LNCaP cells with rotenone or metformin alone led to 20%-
40% decrease in cell viability, while combining either 
of the compounds with the OGT inhibitor led to 80% 
decrease in viability (Figure 2B). We also observed near 
complete growth inhibition upon combinatorial treatment 
(Figure 2C and 2D). Interestingly, while both rotenone and 
metformin modestly decreased the viability and growth 
rates of PNT2 cells, we did not observe any additive 
effects with OGT inhibitor (Figure 2B-2D). These results 
were confirmed with the novel OGT inhibitor OSMI-
1, and combinatorial treatments with either rotenone or 
metformin statistically significantly decreased the viability 
and blocked proliferation of prostate cancer cells but had 
no effect on cells representing normal prostate tissue 
(Suppl. Figure 2A-2C). In addition, treatment of another 
prostate cancer cell line, PC3, with either of the OGT 
inhibitors together with rotenone or metformin statistically 
significantly reduced the viability of cells (Suppl. Figure 
2D).
Extracellular metabolite concentrations can 
reflect the energetic status of the cell, as shown here 
by identifying potential combinatorial treatments to 
inhibit proliferation. However, measuring intracellular 
metabolites provides a more detailed picture of the cellular 
metabolic networks.
Inhibition of O-GlcNAc transferase activity leads 
to depletion of intracellular alanine
Having established that glucose consumption is 
significantly decreased in prostate cancer cells treated 
with OGT inhibitor ST045849, we moved on to evaluate 
the levels of intracellular metabolites. We noted prominent 
accumulation of glucose and a decrease in intracellular 
lactate concentration, in support of decreased glycolysis 
(Figure 3A).
Interestingly, intra-cellular alanine was almost 
completely depleted in LNCaP cells and glutamate was 
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Figure 2: Metabolomic profiling of cell culture media after OGT inhibitor ST045849 treatment. A. LNCaP cells were 
treated with 20µM OGT inhibitor ST045849 for 96 hours, cell media were collected and analyzed by 1H NMR. An example of the obtained 
NMR spectra is shown. The levels of glucose and lactate were determined from the cell culture media by 1H NMR. The data shown is 
an average of seven biological replicates with SEM. The significance was assessed with Student’s t-test, ** < 0.01, *** < 0.001. B. Cells 
were treated as indicated in the figure and the viability of cells was analysed with CTG reagent after 96 hours treatment. Viability of the 
untreated sample was set to 100% and treatments were normalized to this. The data shown is an average of four biological replicates 
with SEM. The significance was assessed with Student’s t-test, ** < 0.01, *** < 0.001. C. and D. Cells were treated as indicated in the 
figure and the growth rate of cells was recorded by life cell imaging. The data shown is an average of four biological replicates with 
SEM. The significance was assessed with Student’s t-test, * < 0.05 and ** < 0.01. Black stars indicate comparison between rotenone (or 
metformin) only and combination of ST045849 with rotenone (or metformin), while red stars indicate comparison between ST045849 and 
combinatorial treatments. 
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decreased. Alanine and glutamate are inter-convertible, 
non-essential amino acids. At the systemic level, alanine 
is part of the alanine cycle, which transports carbon 
skeletons between muscle cells and liver, to signal for 
the need of increased glucose release [28]. Glutamic 
pyruvate transaminase (GPT2, alternative name: alanine 
aminotransferase) is the enzyme catalysing the metabolism 
of alanine (and of α-ketoglutarate) to produce pyruvate and 
glutamate (Figure 3B). Pyruvate can be utilized to support 
the TCA cycle and ATP production. In this context, alanine 
can be considered as an alternative energy source in the 
absence of sufficient glycolysis. In support of this, GPT2 
is induced by starvation (Suppl. Figure 3A and 3B).
OGT inhibition increased the expression of GPT2 
already at 12 hours and increased expression was 
maintained until 96 hours (Figure 3C). Interestingly, the 
intracellular alanine level was decreased by 50% after 48 
hours (Suppl. Figure 3C), and the amino acid was almost 
completely consumed after 96 hours in LNCaP cells 
(Figure 3A). mRNA and metabolomics data support the 
hypothesis that GPT2 is activated in order to consume 
alanine. We next used a GPT2 activity assay to confirm 
that the enzyme activity is increased (Figure 3D). OGT 
inhibition doubled GPT2 activity, when compared to the 
untreated control.
Taken together, these results suggest that OGT 
inhibition triggers cells to rely on alanine as an alternative 
energy source and highlight an important role for the 
GPT2 enzyme.
Inhibition of alanine aminotransferase has 
additive effect with OGT inhibitor
OGT inhibition led to a decrease in glucose 
consumption and to a significantly higher alanine 
consumption. In order to test whether GPT2 activity 
is important for cell survival upon OGT inhibition, we 
used two GPT2 inhibitors: chloro-alanine (Cl-alanine) 
and cycloserine. Combination of either of the two OGT 
inhibitors (ST045849 or OSMI-1) with either of the two 
GPT2 inhibitors led to a statistically significant decrease 
in the viability of LNCaP cells (Figure 4A). Both OGT 
inhibitors sensitized another prostate cancer cell line, 
VCaP, to cyclo-serine (Figure 4B). In addition, OGT 
inhibition sensitized a third prostate cancer cell line (PC3) 
to GPT2 inhibition Suppl. Figure 4A and 4B). We next 
confirmed the small molecule data by inhibiting OGT 
expression with siRNAs and treated cells with Cl-alanine 
(Suppl. Figure 4C). This combinatorial treatment strategy 
also completely blocked proliferation of LNCaP cells and 
inhibited proliferation of PC3 cells (Suppl. Figure 5A-5C).
We next evaluated the combinatorial treatment 
strategy of simultaneous targeting of OGT and GPT2 
in PNT2 cells, and observed that both Cl-alanine and 
cycloserine alone decreased cell viability, but no additive 
effect was observed when both GPT2 and OGT inhibitors 
were combined (Figure 4C). However, combinatorial 
treatment decreased the growth rate of PNT2 cells, albeit 
to a lesser extent than LNCaP cells (Suppl. Figure 5A).
We hypothesised that a cell line derived from 
normal prostate epithelium might be able to slow down 
proliferation due to acute deficiency in energy production, 
while a cell death response would be activated in prostate 
cancer cells. This would explain the discrepancy observed 
between the viability and the growth rate data. In order 
to test this hypothesis, we applied our combinatorial 
treatments to LNCaP and PNT2 cells and evaluated 
caspase 3/7 activation in real-time. Interestingly, caspase 
activation was prominently enhanced by the combinatorial 
treatment with OGT inhibitors and GPT2 inhibitors in 
LNCaP cells but not in PNT2 cells (Figure 5). Of high 
importance, the clinically approved drug, cycloserine, was 
more effective in activating the combinatorial cell death 
response.
DISCUSSION
In this study, we used ST045849, a commercially 
available inhibitor, to study the effect of OGT inhibition 
on prostate cancer cell viability and metabolic 
reprogramming. We first established a compound dose 
that significantly limited the proliferation of prostate 
cancer cells (Figure 1B and 1C). We observed decrease 
in the total-O-GlcNAc levels at 1 hour after the treatment 
(Suppl. Figure 1A). However, total O-GlcNAc levels 
varied from experiment-to-experiment over time points in 
all conditions tested which may reflect the complex role 
of the HBP as a sensor of changes and stresses across a 
range of metabolic processes. Some of this may also at 
the longer time points reflect an adaptation to maintain 
the levels of total-O-GlcNAcylation, through increased 
expression of GFPT1 (Figure 1D and Suppl. Figure 1C 
and 1D).
Consequently, in order to understand the impact 
of targeting OGT on cell growth we needed to look 
beyond total O-GlcNAc levels and down to effects on 
specific genes and proteins. We speculate that proteins 
having only single or few sugar conjugations (such as 
c-MYC [29]) will show regulatory response at low doses 
of OGT inhibitor but this is not evident in the level of 
total O-GlcNAc. OGT regulates target proteins according 
to nutrient availability [10, 30] and growth-promoting 
factors need to be shut-down in the absence of nutrients 
to avoid cell death. However, OGT additionally has 
house-keeping target(s), amongst which nucleoporins 
(NUPs) are highly abundant [31, 32]. Complete block 
of OGT activity leads to decreased O-GlcNAcylation 
and thereby ubiquitinylation and degradation of NUPs, 
which compromises the nuclear pore selectivity filter [31]. 
Certain functions of OGT are important for the survival of 
normal cells, and one option to position OGT as a drug-
target, is to use low dose of inhibitor and try to identify 
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Figure 3: Effects of OGT inhibitor ST045849 on the levels of intracellular metabolites and enzyme activity. A. LNCaP 
cells were treated with OGT inhibitor ST045849 for 96 hours, cell lysates were collected and analysed by 1H NMR. An example of the 
obtained NMR spectra is shown. Quantitation of the 1H NMR data. The data shown is an average of seven biological replicates with SEM. 
The significance was assessed with Student’s t-test, * < 0.05. B. Enzymatic reaction catalysed by GPT2 (glutamic pyruvate transaminase). 
C. Total mRNA was collected from cells treated with OGT inhibitor ST045849 for 12, 24, 48 and 96 hours, and analysed with RT-qPCR. 
OGT inhibitor ST045849 treated samples were normalized to sample without treatment at 12 hours. The data shown is an average of at least 
three biological replicates with SEM and significance was assessed by comparing untreated sample from the corresponding time point, * < 
0.05, ** < 0.01. D. Glutamic pyruvate transaminase (GPT2) assay performed from cell lysates treated either with a vehicle or with 20µM 
of OGT inhibitor ST045849. The GPT2 activity was assessed at 48 hours. The data shown is an average of four biological replicates with 
SEM. The significance was assessed with Student’s t-test, * < 0.05.
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Figure 4: Viability of cells after combinatorial treatment with O-GlcNAc transferase and alanine aminotransferase 
inhibitors. A., B. and C. Cells were treated as indicated in the figure and the viability of cells was assessed after treatment with OGT 
inhibitor ST045849 or OSMI-1 alone or in combination with glutamic pyruvate transaminase (GPT2) inhibitors Cl-alanine or cycloserine. 
The data shown is an average of four biological replicates with SEM and significance was assessed with Student’s t-test, * < 0.05, ** < 
0.01 and *** < 0.001.
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cancer-cell specific vulnerabilities.
In this work, we observed that low dose of 
ST045849 and OSMI-1 treatment was sufficient to 
decrease the expression of AR, c-MYC and CDK1 (Figure 
1D and 1E and Suppl. Figure 1F and 1G). Inhibition of 
OGT expression has been shown to decrease the viability 
and invasion of prostate cancer cells through reduction 
of transcription factor FoxM1 [21]. Interestingly, CDK1 
is required for FoxM1 transcriptional activity during cell 
cycle progression [33, 34]. It appears that decrease OGT 
activity can disrupt this positive cell cycle promoting 
regulatory relationship in prostate cancer cells and it 
remains to be determined if same is true in other cancers. 
Increased CDK1 expression has not been correlated 
with disease progression in prostate cancer, and we show 
that its elevated expression increases the likelihood of 
prostate cancer recurrence (Figure 1F). One of the major 
functions of CDK1 is cell cycle regulation [24], while 
Figure 5: Combinatorial treatment with O-GlcNAc transferase inhibitors and alanine aminotransferase inhibitors 
activates cell death response in prostate cancer cells. A. and B. Activation of caspases 3 and 7 was assessed in real time, imaging 
every 12 hours. The data shown is an average of four biological replicates with SEM and significance was assessed with Student’s t-test, * < 
0.05 and ** < 0.01. Red stars indicate comparison between either of the OGT inhibitors (ST045849 or OSMI-1) combined with Cl-alanine 
against any of the single treatments, while green stars indicate comparison between either of the OGT inhibitors (ST045849 or OSMI-1) 
combined with cycloserine against any of the single treatments.
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OGT itself directly acts on the key cell cycle regulators 
such as HCF-1 [35] and DNA damage response proteins 
[36]. OGT inhibition might sensitize cancer cells to 
DNA damage inducing agents, and this approach clearly 
demands further research.
We next performed metabolic profiling of prostate 
cancer cells after OGT inhibitor treatment. Treatment 
with ST045849 led to decreased glucose consumption 
and lactate production (Figure 2A). This can, at least in 
part, be explained through increased expression of GFPT1, 
to divert glucose into hexosamine biosynthetic pathway 
(Figure 1D). These data suggest that cancer cells decrease 
glycolysis due to OGT inhibition, and might be sensitized 
to inhibitors of oxidative phosphorylation. We confirmed 
this by treating cells with two different OGT inhibitors 
(ST045849 and OSMI-1) and with two inhibitors of 
oxidative phosphorylation, and observed cancer cell 
specific growth blockage (Figure 2B- 2D and Suppl. 
Figure 2).
We believe that small molecule inhibitors represent 
the most effective therapeutic strategy to translate these 
findings into the clinic, even though we did observe a clear 
adaptation to the inhibitor treatment through increased 
expression of GFPT1 (Figure 1D). However, some of the 
desirable effects obtained through OGT inhibition, such 
as decrease in c-MYC, AR and CDK1, were maintained 
(Figure 1D and 1E).
OGT inhibition caused a near-to-complete depletion 
of alanine in LNCaP cells (Figure 3A). Alanine is likely 
consumed by GPT2 as an adaptation to OGT inhibition. 
Interestingly, in the absence of any inhibitor, prostate 
cancer cells accumulate alanine [37], and alanine level is 
also increased in primary samples of prostate cancer [38]. 
Recent advances in magnetic resonance imaging (MRI) 
technology may allow non-invasive, real-time assessment 
of alanine metabolism through hyperpolarized 13C labelled 
pyruvate, which is converted to lactate and alanine in 
prostate cancer[39].
GPT2 can be inhibited with small molecule 
inhibitors Cl-alanine and cycloserine [40]. Cycloserine 
is an FDA-approved drug to treat resistant forms of 
tuberculosis[41], but the drug also inhibits human GPT2, 
as shown previously [40] at similar doses as used in our 
study. Combinatorial treatments strongly inhibited cell 
viability and activated cell death response in prostate 
cancer cells but not in cells representing normal prostate 
tissue (Figure 4 and 5). Notably, GPT2 activity assays 
have been developed and applied successfully to blood 
samples [42].
In this work, we have defined complementary 
inhibitor targets, oxidative phosphorylation and GPT2, 
which can enhance response to OGT inhibition in prostate 
cancer cells. FDA-approved drugs such as metformin 
and cycloserine are available in clinical practice, thereby 
offering accelerated translation of these findings. OGT 
is also of high importance in normal cells [43], and 
combinatorial targeting of OGT and cancer-cell specific 
metabolic abnormalities may allow significant dose 
reduction. GPT2 functions to sustain pyruvate levels 
and mitochondrial activity, which enables non-invasive 
therapy monitoring using hyperpolarized 13C-pyruvate 
MRI. The next steps in taking OGT as a drug target into 
the clinic requires utilization of model organisms to 
better understand potential toxicities and the success of 
combinatorial treatment regimes.
MATERIALS AND METHODS
Cell lines, maintenance and treatments
Cells were obtained from ATCC and were 
maintained according to ATCC guidelines. For 
metabolomic profiling, cells were plated into either 
media with a commercial OGT inhibitor (ST045849, 
TimTec) or a vehicle control (DMSO). O-(2-Acetamido-
2-deoxy-D-glucopyranosylidenamino) N-phenylcarbamate 
(PUGNAc), metformin, rotenone, cycloserine and Cl-
alanine were obtained from Sigma. OSMI-1 compound 
was a gift from Professor Suzanne Walker (Harvard 
Medical School). Cells were allowed to attach for 1 to 
3 days, and then treated as indicated in the beginning of 
the experiment (media was not changed at any point). 
OGT knockdown was performed with Lipofectamine 
RNAiMAX reagent according to manufacturer’s 
instructions (Invitrogen) and OGT targeting siRNAs were 
obtained from Lifetechnologies (s16094 and s16095).
Analysis of viability, growth rate and GPT2- and 
caspase-activity
Cells were plated into 384-well plates one day 
before treatment, unless otherwise stated. Viability was 
determined with cell titer glow (CTG) reagent (Promega). 
Caspase activation (CellPlayer reagent) and growth 
rates were determined with the IncuCyte instrument 
(EssenBiosciences). For GPT2 assays, two million cells 
were plated and activity was assessed with ALT Activity 
Assay (Sigma).
Prepation of cell lysates
For NMR profiling, 350 000 cells were plated 
into three 6-well plate wells, and combined for analysis. 
Media was snap-frozen with liquid nitrogen and stored 
in -80ºC until the analysis. Cells were collected into 
ethanol (-20ºC). After this, cell lysates were centrifuged 
(18 000rpm, 10 minutes), soluble material was transferred 
to a new tube, evaporated with a speedvac and stored in 
-80ºC until analysis. For mRNA profiling, mRNA was 
Oncotarget11www.impactjournals.com/oncotarget
collected with illustraMiniSpin kit (GE Healthcare), 
reverse-transcribed with (qScript cDNA Synthesis Kit, 
Quanta Biosciences), and qPCR was performed with 
primers designed by the Primer3.0 tool (Supplementary 
Table 1).
Preparation of cell lysates for western blotting
Cell lysates were prepared as described 
previously[17] and cell lysis buffer was supplemented 
with protease and phosphatase inhibitors (Roche) and 
PUGNAc. Membranes were probed with antibodies 
against AR (SantaCruz N-20 sc-816), c-MYC (Abcam 
ab32072), CDK1 (CST-9116), GFPT1 (CST-3818), OGT 
(CST- 5368), OGA (Sigma HPA036141), α-Tubulin 
(Millipore CP06) and GAPDH (CST-2118S).
NMR profiling
Cell extracts were dissolved in 600 µl PBS/D2O 
solution containing 1.11 mM trimethylsilyl propionic 
acid (TSP) as a chemical shift reference. 500 µl of culture 
medium and blank culture medium samples (n = 2) were 
mixed with 100 µl PBS/D2O/TSP solution. The samples 
were transferred to 5 mm NMR tubes (Bruker Biospin 
GmbH, Germany) for NMR analysis at the MR Core 
Facility, NTNU, Trondheim, Norway, using a Bruker 
Avance III Ultrashielded Plus 600 MHz spectrometer 
(Bruker Biospin GmbH). The spectrometer was equipped 
with a 5 mm QCI Cryoprobe. Proton spectra were 
acquired using 1D NOESY (Bruker: noesygppr1d) with 
presaturation and spoiler gradients as described previously 
[44]. A standard 1 mM creatine reference solution was 
analyzed under identical experimental conditions and 
used as an external calibration standard. Pre-processing of 
NOESY spectra was performed using TopSpin 3.2 (Bruker 
BioSpin GmbH, Ettlingen, Germany). After 0.30 Hz 
exponential line broadening and Fourier transformation, 
spectra were automatically phase and baseline corrected. 
The chemical shift was calibrated to the TSP peak at 0.0 
ppm. Peak assignments were done according to human 
metabolome database (HMDB; www.hmdb.ca), Chenomx 
NMR Suite 7.0 (Chenomx Inc., Alberta, Canada) and 
previously published data [45]. For cell extracts, the peak 
areas of lactate (1.33 ppm), alanine (1.48 ppm), glutamate 
(2.35 ppm) and glucose (4.64 ppm) and for culture 
mediums, the peak areas of lactate (1.33 ppm) and glucose 
(4.64 ppm) were identified and fitted as Voigt curves by 
polynomial regression (PeakFit v 4.12; Systat Software 
Inc., Chicago, IL, USA). The correlation coefficient of the 
fit (r2) for all spectra was ≥0.95. Absolute concentration 
of individual metabolites were calculated with reference 
to peak area of the standard creatine solution and the cell 
extract samples were normalized to the protein content 
while culture medium samples were normalized to the 
concentration of TSP, according to the PULCON principle 
[46].
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